Comparative Pharmacology
Head-to-head clinical analysis: KETOPROFEN versus PHENYLBUTAZONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETOPROFEN versus PHENYLBUTAZONE.
KETOPROFEN vs PHENYLBUTAZONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis; also inhibits leukotriene synthesis and has direct membrane-stabilizing effects.
Phenylbutazone is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, thereby causing anti-inflammatory, analgesic, and antipyretic effects. It also inhibits leukocyte migration and lysosomal enzyme release.
Oral: 75 mg three times daily or 50 mg four times daily; maximum 300 mg/day. Intravenous: 100 mg every 12-24 hours, infused over 15-30 minutes.
Oral: 100-200 mg three times daily with food; maximum 600 mg/day. For acute gout: initial 400 mg followed by 200 mg every 4-6 hours for 1-2 days, then reduce.
None Documented
None Documented
Clinical Note
moderatePhenylbutazone + Gatifloxacin
"Phenylbutazone may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateKetoprofen + Gatifloxacin
"Ketoprofen may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderatePhenylbutazone + Rosoxacin
"Phenylbutazone may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateKetoprofen + Rosoxacin
"Ketoprofen may increase the neuroexcitatory activities of Rosoxacin."
Terminal elimination half-life: 2-4 hours; clinical context: short half-life allows for quick drug clearance but requires frequent dosing; may be prolonged in elderly or renal impairment.
Terminal elimination half-life is 50–65 hours, but exhibits dose-dependent kinetics; can extend to 72–100 hours with repeated dosing or in elderly.
Renal: ~80% (60% as glucuronide conjugates, 20% as unchanged drug); Biliary/Fecal: ~20% via bile.
Primarily hepatic metabolism; renal excretion of metabolites (<1% unchanged). Biliary/fecal excretion accounts for ~20% of total elimination.
Category D/X
Category C
NSAID
NSAID